GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
GW is developing an oral formulation of purified cannabidiol (CBD), approved as Epidiolex® in the US by the US Food and Drug Administration for seizures associated with Lennox-Gastaut syndrome and Dravet Syndrome, two rare and severe early-onset, drug-resistant epilepsy syndromes.
GW successfully developed the world’s first prescription medicine derived from the cannabis plant, called Sativex® (delta-9-tetrahydrocannibinol and cannabidiol in the EU; nabiximols in the US), which is now approved in over 25 countries outside of the US for the treatment of spasticity due to multiple sclerosis.
The company has a deep pipeline of additional clinical stage cannabinoid product candidates for both orphan and non-orphan indications with a particular focus on neurological conditions.
GW Pharmaceuticals was founded in 1998 and is listed on the NASDAQ Global Market (GWPH). The company has operations in both the US and the UK.